Abstract
Lung cancer is still the leader cause of mortality due to cancer worldwide (1,2). Five-year overall survival (OS) in unresectable and metastatic non-small cell lung cancer (NSCLC) patients (stage IIIB/IV) is less than 5%, regardless of the number of cytotoxic chemotherapy lines given (3). NSCLC is characterized for having different genetic and epigenetic alterations, where high rates of somatic mutations generate a variety of tumor specific antigens that enhance immunogenicity (4). Cancer is the result of the failure of different immunological mechanisms that attempt to eliminate cancer antigens that finally escape the immune system allowing tumor growth (5). Immunotherapy in a very short period of time not only became a reality but also achieved the most spectacular results ever in different types of cancer including NSCLC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
